In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold under brand name Keytruda, in a Phase 3 trial involving lung-cancer patients. Merck shares, which were up ...

Alteogen overtakes EcoPro BM, South Korea’s largest producer of cathodes for EV batteries, to become the biggest company on the Kosdaq by market capitalization.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... to be known under the brand name of Ontruzant and ...

Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...

Merck's vast pipeline, particularly in oncology, should also deliver many more brand-new medicines moving forward. Though its sales will almost certainly decline once Keytruda's patent expires ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

However, Keytruda will be off-patent in 2028 ... has an impressive track record, and can develop brand-new medicines through innovations. The company is an excellent income stock to buy and ...